Merck KGaA Discontinues Clinical Development Program of Tecemotide for Stage III Non-Small Cell Lung CancerSeptember 12, 2014 3:18 pm | News | Comments
Merck KGaA announced that its biopharmaceutical division will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in Stage III non-small cell lung cancer (NSCLC).
The shortage of the medication — called bacillus Calmette-Guerin, or BCG — has been caused by...
The U.S. Food and Drug Administration has granted accelerated approval to Keytruda (...
Pfizer and Merck announced today that they have entered into an agreement to explore the...
Merck & Co. has won federal approval for a new type of sleeping pill designed to help people with insomnia stay asleep. The tablet, Belsomra, works by temporarily blocking chemicals known as orexins that control the sleep cycle and can keep people awake at night.
Merck has reported earnings that more than doubled in its second quarter, and topped analysts' expectations. The Whitehouse Station, New Jersey-based company said net income increased to $2 billion, or 68 cents per share, from $906 million, or 30 cents per share, in the same quarter a year earlier.
Merck Initiates Phase III Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus Infection in High-Risk Bone Marrow Transplant PatientsJuly 24, 2014 8:51 am | News | Comments
The multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of letermovir for the prevention of clinically-significant cytomegalovirus (CMV) infection in adult (18 years and older) CMV-seropositive recipients of allogeneic hematopoietic stem cell transplants.
New details from two studies reveal more side effects from niacin, a drug that hundreds of thousands of Americans take for cholesterol problems and general heart health. Some prominent doctors say the drug now seems too risky for routine use.
Merck KGaA’s biopharmaceutical division today announced the appointment of Luciano Rossetti, M.D., as Executive Vice President and Global Head of Research & Development as of July 21, 2014.
Bionomics Limited has entered into an exclusive Research Collaboration and License Agreement with Merck, known as MSD outside the United States and Canada, for its BNC375 research program targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions.
Merck announced earlier this month that it would pay about $3.85 billion for the Cambridge, Massachusetts-based company. Merck is hoping that teaming Idenix's hepatitis C medicines with its experimental drugs will produce lucrative combo therapies that quickly cure most patients with the blood-borne virus afflicting tens of millions.
Merck and Idenix Pharmaceuticals today announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash. The transaction, which values the purchase of Idenix at approximately $3.85 billion, has been approved by the boards of directors of both companies.
A $100 million settlement involving NuvaRing, a birth-control device linked to sometimes-fatal side effects, will stand now that the vast majority of claimants have chosen to opt into the agreement, those involved in the lawsuits said Thursday.
For decades, seasonal allergy sufferers had two therapy options to ease the misery of hay fever. They could swallow pills or squirt nasal sprays every day for brief reprieves from the sneezing and itchy eyes. Or they could get allergy shots for years to gradually reduce their immune system's...
Merck Animal Health has announced the FDA’s approval of BRAVECTO (fluralaner) chewable tablets for dogs (112.5 mg, 250 mg, 500 mg, 1000 mg, 1400 mg). BRAVECTO is the first and only treatment that has been shown to quickly and effectively kill fleas and multiple tick species for 12 weeks in a single dose.
Santen will make an upfront payment of approximately $600 million and additional payments based on defined sales milestones as needed. The annual sales of these ophthalmology products in the markets within the scope of the agreement are approximately $400 million.
Merck announced that the FDA has approved ZONTIVITY™ (vorapaxar) for the reduction of thrombotic cardiovascular events in patients with a history of heart attack (myocardial infarction) or in patients with narrowing of leg arteries, called peripheral arterial disease (PAD).
The Food and Drug Administration has approved a new type of blood thinner from Merck that reduces heart attack, stroke and other fatal cardiovascular events in patients with a history of heart attack.
Merck & Co. could get an impressive six new prescription medicines approved in the U.S. this year and will soon apply for regulatory approval of two others. That is the word from company executives who addressed analysts during a briefing Tuesday on Merck's business.
Merck today announced that the FDA has accepted for review the Biologics License Application (BLA) for MK-3475, Merck’s investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab.
Bayer AG says it plans to buy Merck's consumer care business, whose products include the Coppertone suncare range, Claritin allergy medicine and the Dr. Scholl's footcare products, for $14.2 billion.
Federal health advisers have voted against a Merck proposal to sell its prescription respiratory pill Singulair as an over-the-counter allergy medication. The Food and Drug Administration's panel of experts voted 11-4 Friday against making the drug available without a prescription.
Merck and Endocyte are stopping a clinical trial of an experimental cancer drug, sending Endocyte shares plunging. The companies said the drug vintafolide didn't slow the progress of ovarian cancer. The trial compared a combination of vintafolide and the chemotherapy drug doxorubicin to doxorubicin and a placebo.
Federal health regulators are weighing the risks of permitting Merck to sell its prescription respiratory pill Singulair as an over-the-counter medicine for allergies. In a review posted online, the FDA raises concerns that the drug could be used inappropriately by teenagers or by patients with more serious conditions, like asthma.
Merck's first-quarter profit rose 7 percent, as heavy cost-cutting offset lower sales due to generic competition and a tax benefit in last year's quarter. The maker of the type 2 diabetes pill Januvia says net income was $1.71 billion, or 57 cents per share.
U.S. regulators have again approved a Merck & Co. tablet for gradually reducing seasonal allergies, this time for ragweed pollen. Ragwitek tablets dissolve quickly under the tongue. Patients are to take one daily for a few years, starting three months before ragweed season begins in late summer.
Merck has announced that FDA has approved GRASTEK ® (Timothy Grass Pollen Allergen Extract) Tablet for Sublingual Use [2800 Bioequivalent Allergy Units (BAU)]. GRASTEK is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis.
Ian C. Read, chairman and CEO of Pfizer, Inc, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) at the trade association’s annual meeting. Also elected were Kenneth C. Frazier, chairman, president and CEO of Merck & Co, Inc., as chairman-elect of the PhRMA Board of Directors, and George A. Scangos, Ph.D., CEO of Biogen Idec, as Board treasurer.
A new class of experimental medicines can dramatically lower cholesterol, raising hopes of a fresh option for people who can't tolerate or don't get enough help from Lipitor and other statin drugs that have been in use for decades.
- Page 1